Latest prices for a box of different versions of larotrectinib announced

Introduction: larotrectinib, also known as larotrectinib, is a first-of-its-kind highly selective tropomyosin receptor kinase (TRK) inhibitor that has been proven effective in adult and pediatric patients with various NTRK gene fusion solid tumors.

The latest prices for one box of different versions of larotrectinib are announced

The latest prices for one box of different versions are as follows.

1. Medical insurance winning bid price: The medical insurance winning bidding price of larotrectinib capsules is 31,500$ per box, and the medical insurance winning bidding price of larotrectinib oral solution is approximately 11,250$ per box. The price after medical insurance reimbursement will be cheaper. For specific prices, you need to consult the local medical insurance department or hospital.

2、老挝卢修斯制药：老挝卢修斯版拉罗替尼的规格是100mgx30粒/盒，其价格大约是1500$-2000$一盒。

3、孟加拉珠峰制药：孟加拉珠峰版拉罗替尼的规格是100mg*30粒/盒，其价格大约是4000$-4500$一盒。

The above prices are for reference only. may be affected by various factors, such as purchase channels, drug versions, medical insurance policies, etc. The actual price at the time of purchase may change.患者在购买时应以实际售价为准，并尽量选择正规渠道购买，以确保药品的质量和安全。

The efficacy of larotrectinib

The efficacy of larotrectinib was determined from three clinical trials in sarcoma patients (≥18 years old) carrying NTRK gene fusions, in which patients received larotrectinib 100 mg orally twice daily. As of the data cutoff, 36 adult patients with TRK fusion sarcoma had begun treatment with larotrectinib: 2 (6%) patients had osteosarcoma, 4 (11%) had gastrointestinal stromal tumor, and 30 (83%) had soft tissue sarcoma.所有患者的反应均可评估，客观反应率为58%。无论之前接受过多少种治疗，患者对拉罗替尼的反应均良好。

Larotrectinib side effects

Adverse reactions are similar in adults and children and include fatigue, myalgia, constipation, nausea and vomiting.一些患者会出现神经症状，例如头晕，尤其是在治疗开始时。在治疗期间应监测肝功能，因为转氨酶浓度可能会升高，一些患者会出现贫血。

Larotrectinib demonstrated robust and durable responses, prolonged survival, and a favorable safety profile in adult patients with TRK fusion sarcoma during long-term follow-up.这些结果继续表明，NTRK基因融合检测应纳入患有各种类型肉瘤的成年患者的临床管理中。